Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...

Bottom Line: Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical ...

A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...

49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society ...

Derek van Amerongen, MD, MS: One of the important topics of discussion within a health plan, whenever we’re discussing treatment A versus treatment B, especially at the P&T discussions, is, what does ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...

Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. Background: There is wide variability in the treatment of metastatic breast ...

ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients ...